Skip to Content

7,743 Results Found

  • Review
  • Open Access
62 Citations
12,142 Views
18 Pages

Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities

  • Abhinav Kanwal,
  • Navjot Kanwar,
  • Sanjay Bharati,
  • Prateek Srivastava,
  • Shailendra P. Singh and
  • Salomon Amar

There are substantial shortcomings in the drugs currently available for treatment of type 2 diabetes mellitus. The global diabetic crisis has not abated despite the introduction of new types of drugs and targets. Persistent unaddressed patient needs...

(This article belongs to the Special Issue Metabolic Syndrome and NASH: From Molecular Basis to Therapy)
  • Review
  • Open Access
70 Citations
14,026 Views
23 Pages

The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery

  • Rocco Savino,
  • Sergio Paduano,
  • Mariaimmacolata Preianò and
  • Rosa Terracciano

29 October 2012

In the modern process of drug discovery, clinical, functional and chemical proteomics can converge and integrate synergies. Functional proteomics explores and elucidates the components of pathways and their interactions which, when deregulated, lead...

(This article belongs to the Special Issue Advances in Proteomic Research)
  • Editorial
  • Open Access
1 Citations
2,167 Views
3 Pages

The intention of this Special Issue is to focus on new aspects of drug discovery, including the search for new molecular targets of various diseases, the creation of new modern methods for diagnosing diseases, the development of new test systems and...

(This article belongs to the Special Issue Frontiers in New Drug Discovery: From Molecular Targets to Preclinical Trials)
  • Review
  • Open Access
274 Citations
76,663 Views
23 Pages

Mycobacterium tuberculosis (M. tb), the causative agent of TB, is a recalcitrant pathogen that is rife around the world, latently infecting approximately a quarter of the worldwide population. The asymptomatic status of the dormant bacteria escalates...

(This article belongs to the Special Issue Latest Review Papers in Molecular Pathology, Diagnostics, and Therapeutics 2023)
  • Article
  • Open Access
12 Citations
5,070 Views
14 Pages

Comparative Genomics of Histoplasma capsulatum and Prediction of New Vaccines and Drug Targets

  • Paula Cristina Silva Almeida,
  • Bruno Stelmastchuk Roque,
  • Andrei Giacchetto Felice,
  • Arun Kumar Jaiswal,
  • Sandeep Tiwari,
  • Vasco Azevedo,
  • Mario León Silva-Vergara,
  • Siomar de Castro Soares,
  • Kennio Ferreira-Paim and
  • Fernanda Machado Fonseca

2 February 2023

Histoplasma capsulatum is a thermodymorphic fungus that causes histoplasmosis, a systemic mycosis that presents different clinical manifestations, ranging from self-limiting to acute lung infection, chronic lung infection and disseminated infection....

(This article belongs to the Special Issue Fungal Neglected Tropical Diseases)
  • Review
  • Open Access
52 Citations
9,347 Views
22 Pages

GPCRs in Intracellular Compartments: New Targets for Drug Discovery

  • Irene Fasciani,
  • Marco Carli,
  • Francesco Petragnano,
  • Francesco Colaianni,
  • Gabriella Aloisi,
  • Roberto Maggio,
  • Marco Scarselli and
  • Mario Rossi

22 September 2022

The architecture of eukaryotic cells is defined by extensive membrane-delimited compartments, which entails separate metabolic processes that would otherwise interfere with each other, leading to functional differences between cells. G protein-couple...

(This article belongs to the Special Issue Molecular Mechanisms of Compartmentalized GPCR Signaling)
  • Article
  • Open Access
7 Citations
3,404 Views
12 Pages

Candida albicans has the capacity to develop resistance to commonly used antimicrobials, and to solve this problem, drug repositioning and new drug combinations are being studied. Nortriptyline, a tricyclic antidepressant, was shown to have the capac...

(This article belongs to the Special Issue Candida albicans Virulence Factors and Its Pathogenecity)
  • Review
  • Open Access
10 Citations
5,710 Views
28 Pages

Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing

  • Vladlena S. Makeeva,
  • Nadezhda S. Dyrkheeva,
  • Olga I. Lavrik,
  • Suren M. Zakian and
  • Anastasia A. Malakhova

27 November 2023

The spectrum of neurodegenerative diseases known today is quite extensive. The complexities of their research and treatment lie not only in their diversity. Even many years of struggle and narrowly focused research on common pathologies such as Alzhe...

(This article belongs to the Special Issue Molecular Advances in Nervous System Disorders)
  • Review
  • Open Access
15 Citations
5,727 Views
25 Pages

The search for new therapeutic targets and their implications in drug development remains an emerging scientific topic. BRCT-bearing proteins are found in Archaea, Bacteria, Eukarya, and viruses. They are traditionally involved in DNA repair, recombi...

(This article belongs to the Special Issue Development of Novel Pharmaceuticals for the Treatment of Parasitic Diseases)
  • Review
  • Open Access
21 Citations
6,175 Views
24 Pages

Yeast as a Model to Find New Drugs and Drug Targets for VPS13-Dependent Neurodegenerative Diseases

  • Joanna Kaminska,
  • Piotr Soczewka,
  • Weronika Rzepnikowska and
  • Teresa Zoladek

Mutations in human VPS13A-D genes result in rare neurological diseases, including chorea-acanthocytosis. The pathogenesis of these diseases is poorly understood, and no effective treatment is available. As VPS13 genes are evolutionarily conserved, th...

(This article belongs to the Special Issue Yeast Models and Molecular Mechanisms of Neurodegenerative Diseases 2.0)
  • Review
  • Open Access
36 Citations
10,641 Views
23 Pages

Alzheimer’s disease (AD) is an incurable, progressive neurodegenerative disorder. AD is a complex and multifactorial disease that is responsible for 60–80% of dementia cases. Aging, genetic factors, and epigenetic changes are the main ris...

(This article belongs to the Special Issue Neurodegenerative Disease: From Molecular Basis to Therapy)
  • Review
  • Open Access
24 Citations
7,387 Views
39 Pages

Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia

  • Kathryn A. Skelding,
  • Daniel L. Barry,
  • Danielle Z. Theron and
  • Lisa F. Lincz

29 December 2022

Acute myeloid leukaemia (AML) is a heterogeneous disease with one of the worst survival rates of all cancers. The bone marrow microenvironment is increasingly being recognised as an important mediator of AML chemoresistance and relapse, supporting le...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Editorial
  • Open Access
1,113 Views
3 Pages

We are pleased to introduce this Special Issue titled ‘New Insight: Enzymes as Targets for Drug Development in Current Issues in Molecular Biology,’ which highlights recent progress and updates in molecular and computational approaches to...

(This article belongs to the Special Issue New Insight: Enzymes as Targets for Drug Development, 2nd Edition)
  • Article
  • Open Access
3 Citations
4,377 Views
17 Pages

Identifying Potential Molecular Targets in Fungi Based on (Dis)Similarities in Binding Site Architecture with Proteins of the Human Pharmacolome

  • Johann E. Bedoya-Cardona,
  • Marcela Rubio-Carrasquilla,
  • Iliana M. Ramírez-Velásquez,
  • Mario S. Valdés-Tresanco and
  • Ernesto Moreno

10 January 2023

Invasive fungal infections represent a public health problem that worsens over the years with the increasing resistance to current antimycotic agents. Therefore, there is a compelling medical need of widening the antifungal drug repertoire, following...

(This article belongs to the Special Issue Converging Nanochemistry: From Disease Prevention to Diagnosis and Treatment)
  • Article
  • Open Access
23 Citations
3,414 Views
22 Pages

Cyclin-Dependent Kinases (CDKs) and the Human Cytomegalovirus-Encoded CDK Ortholog pUL97 Represent Highly Attractive Targets for Synergistic Drug Combinations

  • Markus Wild,
  • Friedrich Hahn,
  • Nadine Brückner,
  • Martin Schütz,
  • Christina Wangen,
  • Sabrina Wagner,
  • Mona Sommerer,
  • Stefan Strobl and
  • Manfred Marschall

24 February 2022

Human cytomegalovirus (HCMV) is a pathogenic human herpesvirus associated with serious, potentially life-threatening symptoms in the immunocompromised or immunonaïve host. The limitations encountered by antiviral therapy options currently availa...

(This article belongs to the Special Issue Host-Cytomegalovirus Interactions: Pro- and Antiviral Key Factors Affecting CMV Infection Outcome or Therapeutic Approaches 3.0)
  • Review
  • Open Access
43 Citations
7,935 Views
25 Pages

Leishmaniasis is a tropical disease caused by a protozoan parasite Leishmania that is transmitted via infected female sandflies. At present, leishmaniasis treatment mainly counts on chemotherapy. The currently available drugs against leishmaniasis ar...

(This article belongs to the Special Issue Development of Novel Pharmaceuticals for the Treatment of Parasitic Diseases)
  • Review
  • Open Access
18 Citations
10,094 Views
24 Pages

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

  • Qi Jin,
  • Dandan Chen,
  • Xiaochun Zhang,
  • Feng Zhang,
  • Dongxiang Zhong,
  • Dawei Lin,
  • Lihua Guan,
  • Wenzhi Pan,
  • Daxin Zhou and
  • Junbo Ge

Pulmonary arterial hypertension (PAH) is a malignant pulmonary vascular syndrome characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, which eventually leads to right heart failure and even death. A...

(This article belongs to the Section Clinical Pharmaceutics)
  • Review
  • Open Access
41 Citations
6,367 Views
23 Pages

Cancer incidence and mortality continue to increase, while the conventional chemotherapeutic drugs confer limited efficacy and relevant toxic side effects. Novel strategies are urgently needed for more effective and safe therapeutics in oncology. How...

(This article belongs to the Special Issue Novel Anticancer Strategies (Volume II))
  • Review
  • Open Access
11 Citations
5,365 Views
17 Pages

Network-Based In Silico Analysis of New Combinations of Modern Drug Targets with Methotrexate for Response-Based Treatment of Rheumatoid Arthritis

  • Marjan Assefi,
  • Kai-Uwe Lewandrowski,
  • Morgan Lorio,
  • Rossano Kepler Alvim Fiorelli,
  • Stefan Landgraeber and
  • Alireza Sharafshah

29 October 2023

Background: Methotrexate (MTX), sulfonamides, hydroxychloroquine, and leflunomide have consistently resulted in remission with relatively mild to moderate adverse effects in patients with rheumatoid arthritis (RA). Modern medications outperform tradi...

(This article belongs to the Section Methodology, Drug and Device Discovery)
  • Article
  • Open Access
11 Citations
5,266 Views
19 Pages

RNAi-Mediated Specific Gene Silencing as a Tool for the Discovery of New Drug Targets in Giardia lamblia; Evaluation Using the NADH Oxidase Gene

  • Jaime Marcial-Quino,
  • Saúl Gómez-Manzo,
  • Francisco Fierro,
  • Yadira Rufino-González,
  • Daniel Ortega-Cuellar,
  • Edgar Sierra-Palacios,
  • America Vanoye-Carlo,
  • Abigail González-Valdez,
  • Angélica Torres-Arroyo and
  • Horacio Reyes-Vivas
  • + 1 author

3 November 2017

The microaerophilic protozoan Giardia lamblia is the agent causing giardiasis, an intestinal parasitosis of worldwide distribution. Different pharmacotherapies have been employed against giardiasis; however, side effects in the host and reports of dr...

(This article belongs to the Section Molecular Genetics and Genomics)
  • Article
  • Open Access
11 Citations
3,867 Views
21 Pages

Molecular Characterization of the Burkholderia cenocepacia dcw Operon and FtsZ Interactors as New Targets for Novel Antimicrobial Design

  • Gabriele Trespidi,
  • Viola Camilla Scoffone,
  • Giulia Barbieri,
  • Giovanna Riccardi,
  • Edda De Rossi and
  • Silvia Buroni

24 November 2020

The worldwide spread of antimicrobial resistance highlights the need of new druggable cellular targets. The increasing knowledge of bacterial cell division suggested the potentiality of this pathway as a pool of alternative drug targets, mainly based...

(This article belongs to the Special Issue FtsZ and RnpA as Valid Targets while Developing Novel Antimicrobials)
  • Editorial
  • Open Access
5 Citations
3,432 Views
3 Pages

20 September 2023

In the dynamic realm of medical research, a resounding chord is struck by recent studies that have propelled drug discovery to new horizons across a spectrum of disciplines [...]

(This article belongs to the Special Issue New Sight: Enzymes as Targets for Drug Development)
  • Article
  • Open Access
5 Citations
2,249 Views
25 Pages

In Silico Approach to Design of New Multi-Targeted Inhibitors Based on Quinoline Ring with Potential Anticancer Properties

  • Żaneta Czyżnikowska,
  • Martyna Mysłek,
  • Aleksandra Marciniak,
  • Remigiusz Płaczek,
  • Aleksandra Kotynia and
  • Edward Krzyżak

Searching for new anticancer drugs is a significant challenge for the medical community due to the current limitations of existing treatments. The primary objective of this study was to design and optimize multi-targeted drug candidates based on a qu...

(This article belongs to the Special Issue Targeted Therapies and Molecular Methods in Cancer, 3rd Edition)
  • Article
  • Open Access
8 Citations
4,237 Views
13 Pages

New Candidates for Biomarkers and Drug Targets of Ischemic Stroke—A First Dynamic LC-MS Human Serum Proteomic Study

  • Aleksandra Turek-Jakubowska,
  • Janusz Dębski,
  • Maciej Jakubowski,
  • Ewa Szahidewicz-Krupska,
  • Jakub Gawryś,
  • Karolina Gawryś,
  • Agnieszka Janus,
  • Małgorzata Trocha and
  • Adrian Doroszko

11 January 2022

(1) Background: The aim of this dynamic-LC/MS-human-serum-proteomic-study was to identify potential proteins-candidates for biomarkers of acute ischemic stroke, their changes during acute phase of stroke and to define potential novel drug-targets. (2...

(This article belongs to the Special Issue New Frontiers in the Clinical Management of Stroke)
  • Review
  • Open Access
52 Citations
21,594 Views
39 Pages

New Drugs and Therapies in Pulmonary Arterial Hypertension

  • Aangi J. Shah,
  • Taylor Beckmann,
  • Mounica Vorla and
  • Dinesh K. Kalra

Pulmonary arterial hypertension is a chronic, progressive disorder of the pulmonary vasculature with associated pulmonary and cardiac remodeling. PAH was a uniformly fatal disease until the late 1970s, but with the advent of targeted therapies, the l...

(This article belongs to the Special Issue Novel Therapeutic Targets for Pulmonary Arterial Hypertension)
  • Review
  • Open Access
380 Citations
20,470 Views
26 Pages

Anti-Angiogenic Therapy: Current Challenges and Future Perspectives

  • Filipa Lopes-Coelho,
  • Filipa Martins,
  • Sofia A. Pereira and
  • Jacinta Serpa

Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. Most of the anti-angiogenic...

(This article belongs to the Special Issue Quo Vadis Cancer Research? On Molecular Mechanisms and Drug Discovery)
  • Article
  • Open Access
3 Citations
3,608 Views
23 Pages

Isolation and Characterization of the First Antigen-Specific EGFRvIII vNAR from Freshwater Stingray (Potamotrygon spp.) as a Drug Carrier in Glioblastoma Cancer Cells

  • Alejandro Manzanares-Guzmán,
  • Andrea C. Alfonseca-Ladrón de Guevara,
  • Elia Reza-Escobar,
  • Mirna Burciaga-Flores,
  • Alejandro Canales-Aguirre,
  • Hugo Esquivel-Solís,
  • Pavel H. Lugo-Fabres and
  • Tanya A. Camacho-Villegas

Glioblastoma is the most common and highly malignant brain tumor in adults. New targeted therapeutic approaches are imperative. EGFRvIII has appealing therapeutic targets using monoclonal antibodies. Thus, endeavors toward developing new mAbs therapi...

(This article belongs to the Special Issue New Agents and Novel Drugs Use for the Oncological Diseases Treatment)
  • Review
  • Open Access
9 Citations
9,189 Views
29 Pages

Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”

  • Gianluca Spitaleri,
  • Pamela Trillo Aliaga,
  • Ilaria Attili,
  • Ester Del Signore,
  • Carla Corvaja,
  • Gloria Pellizzari,
  • Jalissa Katrini,
  • Antonio Passaro and
  • Filippo de Marinis

19 August 2024

RET fusions are relatively rare in Non-Small-Cell Lung Cancers (NSCLCs), being around 1–2% of all NSCLCs. They share the same clinical features as the other fusion-driven NSCLC patients, as follows: younger age, adenocarcinoma histology, low ex...

(This article belongs to the Special Issue Lung Cancer—Molecular Insights and Targeted Therapies (Volume II))
  • Article
  • Open Access
2 Citations
2,623 Views
12 Pages

Analysis of HER2-Low Breast Cancer in Aotearoa New Zealand: A Nationwide Retrospective Cohort Study

  • Annette Lasham,
  • Reenadevi Ramsaroop,
  • Abbey Wrigley and
  • Nicholas Knowlton

20 September 2024

Objectives: To perform the first national analysis of demographic and clinicopathological features associated with the HER2 positive, HER2-low, and HER2-zero invasive breast cancers in New Zealand. The study will reveal the proportion of women who ma...

(This article belongs to the Section Cancer Therapy)
  • Review
  • Open Access
555 Citations
27,985 Views
93 Pages

6 September 2021

Nanoparticles (NPs) have an outstanding position in pharmaceutical, biological, and medical disciplines. Polymeric NPs based on chitosan (CS) can act as excellent drug carriers because of some intrinsic beneficial properties including biocompatibilit...

(This article belongs to the Special Issue Chitosan Functionalizations, Formulations and Composites 2.0)
  • Review
  • Open Access
19 Citations
17,287 Views
26 Pages

11 November 2023

Sarcopenia is a disease characterized by the progressive loss of skeletal muscle mass and function that occurs with aging. The progression of sarcopenia is correlated with the onset of physical disability, the inability to live independently, and inc...

  • Communication
  • Open Access
2,115 Views
10 Pages

27 September 2023

One of the most important aspects of successful cancer therapy is the identification of a target protein for inhibition interaction. Conventionally, this consists of screening a panel of genes to assess which is mutated and then developing a small mo...

(This article belongs to the Section Molecular Pharmacology)
  • Review
  • Open Access
45 Citations
9,484 Views
24 Pages

Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities

  • Stefano Sol,
  • Fabiana Boncimino,
  • Kristina Todorova,
  • Sarah Elizabeth Waszyn and
  • Anna Mandinova

Skin cancer encompasses a range of cutaneous malignancies, with non-melanoma skin cancers (NMSCs) being the most common neoplasm worldwide. Skin exposure is the leading risk factor for initiating NMSC. Ultraviolet (UV) light induces various genomic a...

(This article belongs to the Section Molecular Oncology)
  • Review
  • Open Access
62 Citations
6,942 Views
15 Pages

12 February 2021

The mammalian immune system senses foreign antigens by mechanisms that involve the interplay of various kinds of immune cells, culminating in inflammation resolution and tissue clearance. The ability of the immune cells to communicate (via chemokines...

(This article belongs to the Special Issue Channels and Transporters in Cells and Tissues 2.0)
  • Review
  • Open Access
18 Citations
11,605 Views
17 Pages

Pseudokinases: From Allosteric Regulation of Catalytic Domains and the Formation of Macromolecular Assemblies to Emerging Drug Targets

  • Andrada Tomoni,
  • Jonathan Lees,
  • Andrés G. Santana,
  • Victor M. Bolanos-Garcia and
  • Agatha Bastida

19 September 2019

Pseudokinases are a member of the kinase superfamily that lack one or more of the canonical residues required for catalysis. Protein pseudokinases are widely distributed across species and are present in proteins that perform a great diversity of rol...

(This article belongs to the Special Issue Biocatalysis: Chemical Biosynthesis)
  • Perspective
  • Open Access
74 Citations
7,211 Views
20 Pages

Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates

  • Liliana Rodrigues,
  • Renata Bento Cunha,
  • Tatiana Vassilevskaia,
  • Miguel Viveiros and
  • Celso Cunha

23 April 2022

In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the province of Wuhan, China. Since then, there have been over 400 million co...

(This article belongs to the Special Issue Drug Design and Discovery for Treatment of Coronavirus Disease (COVID-19))
  • Article
  • Open Access
9 Citations
3,596 Views
14 Pages

Cancer Stem Cells and Somatic Stem Cells as Potential New Drug Targets, Prognosis Markers, and Therapy Efficacy Predictors in Breast Cancer Treatment

  • Olga Pershina,
  • Natalia Ermakova,
  • Angelina Pakhomova,
  • Darius Widera,
  • Edgar Pan,
  • Mariia Zhukova,
  • Elena Slonimskaya,
  • Sergey G. Morozov,
  • Aslan Kubatiev and
  • Evgenii G. Skurikhin
  • + 1 author

14 September 2021

New drug targets, markers of disease prognosis, and more efficient treatment options are an unmet clinical need in breast cancer (BC). We have conducted a pilot study including patients with luminal B stage breast cancer IIA–IIIB. The presence and fr...

(This article belongs to the Special Issue Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021))
  • Article
  • Open Access
4 Citations
3,160 Views
20 Pages

Non-Hereditary Obesity Type Networks and New Drug Targets: An In Silico Approach

  • Styliani A. Geronikolou,
  • Athanasia Pavlopoulou,
  • Merve Uça Apaydin,
  • Konstantinos Albanopoulos,
  • Dennis V. Cokkinos and
  • George Chrousos

Obesity, a chronic, preventable disease, has significant comorbidities that are associated with a great human and financial cost for society. The aim of the present work is to reconstruct the interactomes of non-hereditary obesity to highlight recent...

(This article belongs to the Special Issue 25 Anniversary of Bioinformatics of Genome Regulation and Structure Conference Series)
  • Editorial
  • Open Access
6 Citations
8,132 Views
12 Pages

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–4

  • Arduino A Mangoni,
  • Catherine Guillou,
  • Jean Jacques Vanden Eynde,
  • Christopher Hulme,
  • Josef Jampilek,
  • Wei Li,
  • Katalin Prokai-Tatrai,
  • Jarkko Rautio,
  • Simona Collina and
  • Diego Muñoz-Torrero
  • + 15 authors

31 December 2018

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes is a series of Editorials, which is published on a biannual basis by the Editorial Board of the Medicinal Chemistry section of the journal Molecules. [...]

(This article belongs to the Collection Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes)
  • Editorial
  • Open Access
7 Citations
10,933 Views
24 Pages

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6

  • Jean Jacques Vanden Eynde,
  • Arduino A. Mangoni,
  • Jarkko Rautio,
  • Jérôme Leprince,
  • Yasu-Taka Azuma,
  • Alfonso T. García-Sosa,
  • Christopher Hulme,
  • Josef Jampilek,
  • Rafik Karaman and
  • Diego Muñoz-Torrero
  • + 32 authors

28 December 2019

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes is a series of Editorials that is published on a biannual basis by the Editorial Board of the Medicinal Chemistry section of the journal Molecules [...]

(This article belongs to the Special Issue Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes 2020)
  • Editorial
  • Open Access
3 Citations
7,765 Views
14 Pages

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–5

  • Arduino A. Mangoni,
  • Jean Jacques Vanden Eynde,
  • Josef Jampilek,
  • Dimitra Hadjipavlou-Litina,
  • Hong Liu,
  • Jóhannes Reynisson,
  • Maria Emília Sousa,
  • Paula A. C. Gomes,
  • Katalin Prokai-Tatrai and
  • Diego Muñoz-Torrero
  • + 16 authors

30 June 2019

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes is a series of Editorials which is published on a biannual basis by the Editorial Board of the Medicinal Chemistry section of the journal Molecules [...]

(This article belongs to the Collection Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes)
  • Editorial
  • Open Access
8 Citations
10,364 Views
21 Pages

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–7

  • Michael Gütschow,
  • Jean Jacques Vanden Eynde,
  • Josef Jampilek,
  • CongBao Kang,
  • Arduino A. Mangoni,
  • Paola Fossa,
  • Rafik Karaman,
  • Andrea Trabocchi,
  • Peter J. H. Scott and
  • Diego Muñoz-Torrero
  • + 38 authors

28 June 2020

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes is a series of editorials which is published on a biannual basis by the Editorial Board of the Medicinal Chemistry section of the journal Molecules [...]

(This article belongs to the Special Issue Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes 2020)
  • Editorial
  • Open Access
4 Citations
6,709 Views
9 Pages

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–2

  • Diego Muñoz-Torrero,
  • Arduino A. Mangoni,
  • Hong Liu,
  • Christopher Hulme,
  • Jarkko Rautio,
  • Rafik Karaman,
  • Maria Emília De Sousa,
  • Katalin Prokai-Tatrai,
  • Jean-Marc Sabatier and
  • Luigi A. Agrofoglio
  • + 7 authors

28 December 2017

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes is a series of Editorials, which are published on a biannual basis by the Editorial Board of the Medicinal Chemistry section of the journal Molecules [...]

(This article belongs to the Collection Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes)
  • Article
  • Open Access
5 Citations
3,336 Views
22 Pages

A Shortcut from Genome to Drug: The Employment of Bioinformatic Tools to Find New Targets for Gastric Cancer Treatment

  • Daiane M. S. Brito,
  • Odnan G. Lima,
  • Felipe P. Mesquita,
  • Emerson L. da Silva,
  • Maria E. A. de Moraes,
  • Rommel M. R. Burbano,
  • Raquel C. Montenegro and
  • Pedro F. N. Souza

Gastric cancer (GC) is a highly heterogeneous, complex disease and the fifth most common cancer worldwide (about 1 million cases and 784,000 deaths worldwide in 2018). GC has a poor prognosis (the 5-year survival rate is less than 20%), but there is...

(This article belongs to the Section Drug Targeting and Design)
  • Review
  • Open Access
47 Citations
11,481 Views
33 Pages

29 March 2020

New drugs with new mechanisms of action are urgently required to tackle the global tuberculosis epidemic. Following the FDA-approval of the ATP synthase inhibitor bedaquiline (Sirturo®), energy metabolism has become the subject of intense focus a...

(This article belongs to the Special Issue Tuberculosis Drug Discovery and Development 2019)
  • Feature Paper
  • Review
  • Open Access
88 Citations
30,380 Views
35 Pages

27 March 2020

Eighty years after the introduction of the first antituberculosis (TB) drug, the treatment of drug-susceptible TB remains very cumbersome, requiring the use of four drugs (isoniazid, rifampicin, ethambutol and pyrazinamide) for two months followed by...

(This article belongs to the Special Issue Tuberculosis Drug Discovery and Development 2019)
  • Article
  • Open Access
11 Citations
3,294 Views
10 Pages

12 November 2022

Bordetella pertussis is a Gram-negative bacterium known to cause pertussis or whooping cough. The disease affects the respiratory system and is contagious. Pertussis causes high mortality among infants aged less than one-year-old, although it can aff...

  • Article
  • Open Access
23 Citations
3,782 Views
13 Pages

Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations

  • Serena Stamatakos,
  • Giovanni Luca Beretta,
  • Elisabetta Vergani,
  • Matteo Dugo,
  • Cristina Corno,
  • Elisabetta Corna,
  • Stella Tinelli,
  • Simona Frigerio,
  • Emilio Ciusani and
  • Laura Gatti
  • + 2 authors

10 May 2021

Metabolic changes promoting cell survival are involved in metastatic melanoma progression and in the development of drug resistance. In BRAF-inhibitor resistant melanoma cells, we explored the role of FASN, an enzyme involved in lipogenesis overexpre...

(This article belongs to the Special Issue Combination Therapies in Cancers)
  • Review
  • Open Access
56 Citations
10,302 Views
14 Pages

TRPM4 in Cancer—A New Potential Drug Target

  • Anna Borgström,
  • Christine Peinelt and
  • Paulina Stokłosa

5 February 2021

Transient receptor potential melastatin 4 (TRPM4) is widely expressed in various organs and associated with cardiovascular and immune diseases. Lately, the interest in studies on TRPM4 in cancer has increased. Thus far, TRPM4 has been investigated in...

(This article belongs to the Special Issue Transient Receptor Potential (TRP) Channels: Markers and Therapeutic Targets for Cancer?)
  • Article
  • Open Access
60 Citations
6,702 Views
19 Pages

Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity

  • Friedrich Hahn,
  • Stuart T. Hamilton,
  • Christina Wangen,
  • Markus Wild,
  • Jintawee Kicuntod,
  • Nadine Brückner,
  • Jasmine E. L. Follett,
  • Lars Herrmann,
  • Ahmed Kheimar and
  • Manfred Marschall
  • + 3 authors

27 November 2021

Human cytomegalovirus (HCMV) is a major pathogenic herpesvirus that is prevalent worldwide and it is associated with a variety of clinical symptoms. Current antiviral therapy options do not fully satisfy the medical needs; thus, improved drug classes...

(This article belongs to the Section Macromolecules)

of 155